Medtronic reports 8.4% revenue growth in FY26, highest in decade; guides FY27 to 6.75%-7.25%

Filed June 3, 2026 · Period ending June 3, 2026 · ~1 min read

Key Changes

• high

  FY26 revenue reached $36.4B, up 8.4% reported and 5.8% organic—the company's strongest annual growth in 10 years. Q4 revenue of $9.8B grew 9.9% reported, beating guidance by 90 basis points.

  Exhibit 99.1 verify on EDGAR →
• high

  FY27 organic revenue growth guided to 6.75%-7.25% (includes 53rd week benefit and full-year Diabetes revenue). Non-GAAP EPS guided to $5.90-$6.00, representing 6.7%-8.5% growth.

  Exhibit 99.1 verify on EDGAR →
• high

  Non-GAAP operating margin declined 130 basis points in FY26 (150 bps constant currency), impacted by 45 bps from MiniMed Blackstone payment and 50 bps from tariffs.

  Exhibit 99.1 verify on EDGAR →